Tesaro (TSRO) PT Raised to $120 at Baird

BofA/Merrill Lynch Upgrades Tesaro (TSRO) to Buy

BofA/Merrill Lynch upgraded Tesaro (NASDAQ: TSRO) from Neutral to Buy with a price target of $123.00.

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $99.26 yesterday.

Tesaro (TSRO) PT Raised to $128 at RBC Capital

RBC Capital analyst Adnan Butt reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $128.00 (from $122.00) following NOVA Phase 3 trial details.

Butt commented, "Details show biomarker/HRD-positive benefit is not driven by somatic BRCA patients alone, biomarker/HRD-negative... More

Tesaro (TSRO) PT Raised to $122 at Credit Suisse

Credit Suisse analyst Alethia Young reiterated an Outperform rating and boosted her price target on Tesaro (NASDAQ: TSRO) to $122.00 (from $90.00) saying the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. They also think the robustness of this data bodes well from... More

TESARO (TSRO), ENGOT Announce Niraparib Phase 3 ENGOT-OV16/NOVA Met Primary Endpoint

TESARO, Inc. (Nasdaq: TSRO) and ENGOT, the European Network for Gynaecological Oncological Trial groups, announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress, the congress of the European Society for Medical Oncology (ESMO), by Dr. Mansoor Raza Mirza, M.D., Medical Director of the Nordic Society of Gynecologic Oncology (NSGO) and principal investigator on the ENGOT-OV16/NOVA trial. These data were discussed during the ESMO press briefing in Copenhagen as part of the congress, and were simultaneously published online in the New England Journal of... More

Myriad Genetics (MYGN) Announces Strong Data from myChoice HRD Test in Ovarian Cancer (TSRO)

Myriad Genetics, Inc. (Nasdaq: MYGN) announced that its myChoice HRD test identified more than double the number of... More

Tesaro (TSRO) PT Raised to $139 at Wedbush

Wedbush analyst David Nierengarten reiterated an Outperform rating and boosted his price target on Tesaro (NASDAQ: TSRO) to $139.00 (from $107.00) as the NOVA trial data supports possible approval in all platinum-sensitive patients.

Nierengarten commented, "We see the clinical benefit of niraparib in... More

TESARO (TSRO) Presents Statistically Significant Phase 3 ENGOT-OV16/NOVA Trial Results at ESMO

Over the weekend, TESARO, Inc. (NASDAQ: TSRO) and ENGOT, the European Network for Gynaecological Oncological Trial groups, today announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress, the congress of the European Society for Medical Oncology (ESMO), by Dr. Mansoor Raza Mirza, M.D., Medical Director of the Nordic Society of Gynecologic Oncology (NSGO) and principal investigator on the ENGOT-OV16/NOVA trial. These data were discussed during the ESMO press briefing in Copenhagen as part of the congress, and were simultaneously published online in the New... More

Tesaro (TSRO) PT Raised to $115 at Leerink Following Full Results of Ph 3 NOVA Trial

Leerink Partners analyst Seamus Fernandez reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $115.00 (from $108.00) after full results of the Ph 3 NOVA trial (niraparib as 2L maintenance for ovarian cancer) presented in a Presidential Session at ESMO and... More